Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Nao Sugihara , Yoshikiyo Okada
, Akira Tomioka
, Suguru Ito
, Rina Tanemoto
, Shin Nishii
, Akinori Mizoguchi
, Kenichi Inaba
, Yoshinori Hanawa
, Kazuki Horiuchi
, Akinori Wada
, Yoshihiro Akita
, Masaaki Higashiyama
, Chie Kurihara
, Shunsuke Komoto
, Kengo Tomita
, Ryota Hokari
Correspondence to: Yoshikiyo Okada
ORCID https://orcid.org/0000-0002-4628-3881
E-mail gasjet@ndmc.ac.jp
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver.
Published online June 9, 2023
Copyright © Gut and Liver.
Background/Aims: Recent studies indicate that probiotics, which have attracted attention as a treatment for irritable bowel syndrome, affect intestinal homeostasis. In this study, we investigated whether Zygosaccharomyces sapae (strain I-6), a probiotic yeast isolated from miso (a traditional Japanese fermented food), could improve irritable bowel syndrome symptoms.
Methods: Male Wistar rats were exposed to water avoidance stress (WAS). The number of defecations during WAS and the visceral hypersensitivity before and after WAS were evaluated using colorectal distension. Tight junction changes were assessed by Western blotting. Some rats were fed with strain I-6 or β-glucan from strain I-6. Changes in the intestinal microbiota were analyzed. The effect of fecal microbiota transplantation after WAS was evaluated similarly. Caco-2 cells were stimulated with interleukin-1β and tight junction changes were investigated after coculture with strain I-6.
Results: The increased number of stool pellets and visceral hypersensitivity induced by WAS were suppressed by administering strain I-6. The decrease in tight junction protein occludin by WAS was reversed by the administration of strain I-6. β-Glucan from strain I-6 also suppressed those changes induced by WAS. In the rat intestinal microbiota, treatment with strain I-6 altered the β-diversity and induced changes in bacterial occupancy. Upon fecal microbiota transplantation, some symptoms caused by WAS were ameliorated.
Conclusions: These results suggest that traditional fermented foods such as miso in Japan are valuable sources of probiotic yeast candidates, which may be useful for preventing and treating stress-induced visceral hypersensitivity.
Keywords: Irritable bowel syndrome, Yeasts, Fermented foods, Tight junction proteins, Gut microbiota
The intestinal epithelial barrier is one of the most important factors in protecting gut homeostasis from continuous exposure to microbial pathogens and antigens, and is simultaneously responsible for nutrient and water uptake.1 Many previous studies have demonstrated that patients with irritable bowel syndrome (IBS) show dysfunction of the intestinal epithelial barrier and gut microbiota, which have been linked with visceral hypersensitivity and pain.2-6 Several studies have suggested mast cells as crucial effector cells of stress-induced stimulation in the intestine, which release multifunctional mediators such as proteases and histamine, leading to increase visceral hyper sensitivity.7 A recent study has shown that increases in epithelial permeability and mast cell activation by psychological stress were stronger in the small intestine than in the colon in the rats, suggesting importance of small intestinal injury in the stress-induced visceral hypersensitivity.8 Tight junctions (TJs) are essential for intestinal barrier function and regulate the paracellular permeability of materials.9 TJs are composed of more than 50 proteins including occludin family members which are transmembrane proteins.10
Recently, probiotics have been attracting increasing attention as a treatment for IBS, as many previous studies have shown that probiotics influence intestinal homeostasis, such as intestinal barrier functions, through TJ complex regulation.11-14 Traditional Japanese fermented foods contain not only eubacteria but also yeasts classified as fungi. In addition to probiotic strains belonging to eubacteria, yeasts have also been used as probiotics for treating IBS.12 However, few studies have examined the effects of yeasts from traditional Japanese fermented foods on IBS.
Miso, a fermented soybean product made from rice or barley malt and salt, is one of the most popular traditional Japanese fermented foods and seasonings. The fermentation process of miso is known to include many species of yeasts and other microorganisms.15 Miso has been reported to have positive effects in several human health conditions.16 We previously isolated a probiotic yeast strain,
In this study, we examined the effects of strain I-6 and its β-glucan on intestinal barrier dysfunction, visceral hypersensitivity in response to colorectal distension, and gut microbiota modulation in a rat model of IBS induced by water avoidance stress (WAS). To investigate the effect of strain I-6 on modulating the barrier functions of intestinal epithelial cells
Four-week-old male Wistar rats were purchased from Japan SLC Inc. (Shizuoka, Japan). Rats were housed in plastic cages with normal 12-hour light-dark cycles at a temperature of 23℃ to 24℃ with 55% humidity. The rats were fed a standard laboratory diet (CLEA Japan, Tokyo, Japan) and had free access to food and water. Laboratory animals were used in accordance with the guidelines of the “Methods and Welfare Considerations in Behavioral Research with Animals: report of a National Institutes of Health Workshop” published by the US National Institutes of Health (Bethesda, MD, USA) along the guidelines of the animal facility at the National Defense Medical College in Japan. All experimental protocols were approved by the Animal Research Committee of the National Defense Medical College (No. 18002).
Strain I-6 was obtained from our laboratory collection.17 Living strain I-6 cells were fed to the rats
Rats were divided into three groups: sham WAS+vehicle group, WAS+vehicle group, and WAS+I-6 or β-glucan group. The animals were given water with or without strain I-6 or β-glucan for 6 weeks as a pre-intervention and allowed to drink throughout the experiment. After pre-intervention, chronic WAS in rats was used as a model of IBS (Fig. 1).20,21 The WAS protocol has been described in previous reports.22 Briefly, WAS rats were placed on a glass platform (10×10 cm) in the middle of a box (46.5×37×24 cm) filled with water (23℃) to 1 cm below the height of the platform for 60 minutes per day. The rats were placed on the platform, sham WAS rats were placed in a box without water. We counted the number of stool pellets while rats were receiving WAS for 60 minutes.
Visceral hypersensitivity was evaluated using colorectal distension, as previously described with a barostatometer (Distender Series IIR; G&J Electronics Inc., Toronto, ON, Canada).23 Rats were placed in an acrylic case, and a collapsible balloon was inserted 4 cm beyond the anus of each rat under anesthesia. Balloon pressure was increased at a constant rate of 1 mm Hg/s, and the threshold of the abdominal withdrawal reflex (AWR) was measured three times; the mean value was taken as the threshold AWR value. We performed colorectal distension on the day before the start of WAS (day 0) and on the day after the end of the WAS (day 11). the changes in AWR on day 11 from day 0 (baseline) were calculated and compared among groups.
Four-week-old male Wistar rats were purchased and bred as previously described. Rats were given water with strain I-6 at a concentration of 5×106 colony-forming units per milliliter for 6 weeks, followed by collection of fresh stools. For the control groups, water was given (n=2) for free drinking. The stool samples were diluted 10-fold with phosphate-buffered saline.
Seven-week-old male Wistar rats were purchased and divided into the control group (WAS+control stool) and the I-6 group (WAS+I-6 stool) (n=6). Rats were anesthetized using isoflurane and 1 mL of stool was transgastrically administered twice daily during the WAS treatment. Visceral hypersensitivity was compared between the two groups.
Caco-2 was obtained from Riken BRC (Tsukuba, Japan) and maintained in Dulbecco’s modified Eagle’s medium containing 15% fetal bovine serum, 1% nonessential amino acids, and 1% penicillin-streptomycin solution at 37℃ and 5% CO2. The number of passages was approximately 20–40 and 1×106 cells were seeded in 6-well plates and used after 21 days with medium changes every 2 days. Cells were stimulated with recombinant interleukin-1β (IL-1β; 10 ng/mL) (Proteintech Group, Inc., Rosemont, IL, USA) at 6 hours before cell harvest. In some experiments, cells were pretreated with strain I-6 (80 µg/mL) at 48 hours before cell harvest. In some experiments, anti-Dectin-1 antibody (0.2 ng/mL) (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-TLR2 antibody (0.2 ng/mL) (Abcam, Cambridge, UK) were added 30 minutes before treatment with strain I-6.
Ileal end tissues and Caco-2 cells were homogenized in 0.5% sarcosylic acid-containing protease inhibitor (Roche Diagnostics K.K., Tokyo, Japan) and phosphatase inhibitor (Roche Diagnostics K.K.). The samples were shaken every 5 minutes for 30 minutes and then centrifuged for 5 minutes at 14,000 rpm at 4℃. The protein concentration was assessed using a DC protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). A total of 25 µg of proteins were separated in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 45 minutes at 200 V using Electrophoresis Power Supply EPS 1001 (Amersham Pharmacia Biotech, GE Healthcare, Brooklyn, NY, USA). Then it was transferred onto polyvinylidene difluoride membranes for 30 minutes at 12 V using BP-312 (BIO CRAFT, Tokyo, Japan). Membranes were blocked with 5% skim milk or 3% bovine serum albumin dissolved in phosphate buffered saline with tween 20 and incubated with the primary antibodies to occludin (Abcam) (1:1,000) and β-actin (Abcam) (1:4,000) at 4℃ overnight. After washing, the blots were incubated with anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) (1:4,000) for 1 hour at room temperature. Protein bands were detected using Clarity Western ECL Substrate (Bio-Rad Laboratories Inc.). Blot images were electronically scanned using ChemiDoc Touch (Bio-Rad Laboratories Inc.).
Stool samples were collected from sham WAS+vehicle group, sham WAS+I-6 group, WAS+vehicle group and WAS+I-6 group after completion of WAS protocol and stored at –80℃. Bacterial DNA was extracted from stool samples using the QIAamp Fast DNA stool mini kit (Qiagen, Valencia, CA, USA). The variable region V3-4 of the 16S rRNA was amplified twice by PCR using specified primers and Nextera XT Index Kit (Illumina, San Diego, CA, USA). The PCR products were purified by AMPure XP beads (Beckman Coulter Genomics, Brea, CA, USA). Library quantification, normalization, and pooling were performed according to the 16S Metagenomic Sequencing Library Preparation (Illumina). The size and quality of the pooled libraries were ascertained using MultiNA (Shimadzu Corp., Kyoto, Japan). Following NaOH denaturation, the libraries were loaded into the MiSeq reagent kit V3 and sequenced on a MiSeq instrument (Illumina). The sequence data were analyzed using the Quantitative Insights Into Microbial Ecology 2 tool.24
Comparisons among groups were undertaken using one-way analysis of variance followed by the Tukey-Kramer
WAS treatment significantly increased the number of stool pellet output per hour compared to sham WAS treatment. The WAS with strain I-6 group significantly suppressed increase in the number of stool pellets output compared to the WAS with vehicle group (Fig. 2A). In addition, WAS treatment significantly decreased the AWR threshold compared to sham WAS treatment. The WAS with I-6 group significantly suppressed the decrease in the AWR threshold compared to the WAS with vehicle group (Fig. 2B).
Increased intestinal permeability through a decrease in the TJ protein occludin results in altered intestinal permeability in IBS.25-27 The Western blotting analysis showed that the expression of occludin was decreased in the WAS with vehicle group compared to the sham WAS with vehicle group (Fig. 2C and D). This reduction was significantly inhibited by the addition of I-6 to the WAS treatment (Fig. 2C).
Furthermore, we investigated whether β-glucan extracted from the cell bodies of I-6 altered stress-induced visceral hypersensitivity, as many previous studies have shown that β-glucan is a major structural component of various yeast cells and is a potent biological agent for human and rodent experimental models.25-28
There was a significant increase in the number of stool pellets in the WAS with vehicle group compared to the sham WAS with vehicle group (Fig. 3A), but this was significantly lower in the WAS with β-glucan group compared to the WAS with vehicle group (Fig. 3A). Further, a decrease in the AWR threshold value was observed in the WAS with vehicle group compared to the sham WAS with vehicle group; these reductions were alleviated in the WAS with β-glucan group (Fig. 3B).
Analysis of the collected stool pellets showed no difference in α-diversity (Fig. 4A). In contrast, principal coordinate analysis for β-diversity indicated that the sham WAS+I-6 group had a distinctly different distribution (Fig. 4B and D) and showed significant difference by permutational multivariate analysis of variance analysis (Fig. 4C and E). The mean UniFrac distance analysis (unweighted) showed that the mean UniFrac distance between the sham WAS+vehicle group and the sham WAS+I-6 group was significantly higher than that within the sham WAS+vehicle group and within the sham WAS+I-6 group (Fig. 4B and C). Further analysis (weighted) showed that the mean UniFrac distance between the sham WAS+vehicle group and the sham WAS+I-6 group was significantly higher than that within the sham WAS+vehicle group and the sham WAS+I-6 group (Fig. 4D and E).
The composition of the gut microbiota was also analyzed. At the phylum level, there was no significant difference between the two groups in the five phyla with more than 1% abundance (Fig. 4F). At the genus level, in 29 genera with more than 1% abundance, the sham WAS+vehicle group showed significant changes in the abundance of 13 species (Fig. 4G). We applied LEfSe analysis to explore the taxa that best discriminated bacterial populations between the two groups. In the sham WAS+I-6 group, we found a pronounced deposition of the
The composition of the gut microbiota was also analyzed in stress-received animals. At the phylum level, there was no significant difference between the two groups in the five phyla with more than 1% abundance (Fig. 5A). At the genus level, in 37 genera with more than 1% abundance, the WAS+I-6 group showed significant changes in the abundance of 14 species (Fig. 5B).
To investigate whether changes in the gut microbiota are involved in the pathophysiology of the ameliorating effect of strain I-6 on stress-induced visceral hypersensitivity, we investigated whether amelioration of stress-induced visceral hypersensitivity in WAS-treated rats was transferrable by FMT from I-6 treated animals. We then compared the number of stool pellets and AWR of the control group with that of the I-6 group (Fig. 6A). There was no significant difference in the number of stool pellets (Fig. 6B). The AWR threshold value of the I-6 group was significantly higher than that of the control group (Fig. 6C).
Finally, we investigated the mechanism of I-6-induced modification of occludin expression
Here, we showed that oral administration of I-6 and β-glucan of strain I-6 ameliorated the symptoms in a rat model of IBS. The magnitude of visceral hypersensitivity and number of stool pellets were significantly smaller in the WAS with I-6 group compared with those in the WAS group. Additionally, stress-induced reduction of occludin expression in the WAS group was significantly ameliorated by I-6 treatment (Fig. 2). A previous study has reported that IBS symptoms are accompanied with an increase in intestinal permeability in a rat model of IBS, and that occludin is decreased during this process.5 Furthermore, increased intestinal permeability through a decrease in TJ proteins such as occludin is one of the main pathogenic features of human IBS, and its improvement is an important target of IBS treatment.2,4,13 These findings suggest that I-6 ameliorated the symptoms in a rat model of IBS by recovering intestinal permeability through increased occludin expression.
We then investigated whether strain I-6 directly increased the expression of occludin in intestinal epithelial cells
Although the effect of I-6 on the rat IBS model has been explained by increasing intestinal permeability, we also investigated the effects of oral administration of strain I-6 on gut microbiota, because dysbiosis is involved in the pathogenesis of IBS, and a systematic review or meta-analysis showed the usefulness of probiotic therapy in the treatment of IBS.36,37 Surprisingly, high-throughput sequencing of the gut microbiota showed significant changes in β-diversity after oral administration of strain I-6 (Fig. 4B-E). In the genus-level composition of the gut microbiota,
In conclusion,
This research was supported by grants from the National Defense Medical College.
No potential conflict of interest relevant to this article was reported.
Study concept and design: N.S., Y.O., R.H. Data acquisition: N.S., Y.O., A.T., S.I., R.T., S.N., A.M., K.I., Y.H., K.H., A.W., Y.A., M.H., C.K., S.K., K.T., R.H. Data analysis and interpretation: N.S., Y.O., R.H. Drafting of the manuscript: N.S. Critical revision of the manuscript for important intellectual content: N.S., Y.O., R.H. Statistical analysis: N.S., Y.O., R.H. Administrative, technical, or material support; study supervision: Y.O., R.H. Approval of final manuscript: all authors.
Gut and Liver
Published online June 9, 2023
Copyright © Gut and Liver.
Nao Sugihara , Yoshikiyo Okada
, Akira Tomioka
, Suguru Ito
, Rina Tanemoto
, Shin Nishii
, Akinori Mizoguchi
, Kenichi Inaba
, Yoshinori Hanawa
, Kazuki Horiuchi
, Akinori Wada
, Yoshihiro Akita
, Masaaki Higashiyama
, Chie Kurihara
, Shunsuke Komoto
, Kengo Tomita
, Ryota Hokari
Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
Correspondence to:Yoshikiyo Okada
ORCID https://orcid.org/0000-0002-4628-3881
E-mail gasjet@ndmc.ac.jp
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background/Aims: Recent studies indicate that probiotics, which have attracted attention as a treatment for irritable bowel syndrome, affect intestinal homeostasis. In this study, we investigated whether Zygosaccharomyces sapae (strain I-6), a probiotic yeast isolated from miso (a traditional Japanese fermented food), could improve irritable bowel syndrome symptoms.
Methods: Male Wistar rats were exposed to water avoidance stress (WAS). The number of defecations during WAS and the visceral hypersensitivity before and after WAS were evaluated using colorectal distension. Tight junction changes were assessed by Western blotting. Some rats were fed with strain I-6 or β-glucan from strain I-6. Changes in the intestinal microbiota were analyzed. The effect of fecal microbiota transplantation after WAS was evaluated similarly. Caco-2 cells were stimulated with interleukin-1β and tight junction changes were investigated after coculture with strain I-6.
Results: The increased number of stool pellets and visceral hypersensitivity induced by WAS were suppressed by administering strain I-6. The decrease in tight junction protein occludin by WAS was reversed by the administration of strain I-6. β-Glucan from strain I-6 also suppressed those changes induced by WAS. In the rat intestinal microbiota, treatment with strain I-6 altered the β-diversity and induced changes in bacterial occupancy. Upon fecal microbiota transplantation, some symptoms caused by WAS were ameliorated.
Conclusions: These results suggest that traditional fermented foods such as miso in Japan are valuable sources of probiotic yeast candidates, which may be useful for preventing and treating stress-induced visceral hypersensitivity.
Keywords: Irritable bowel syndrome, Yeasts, Fermented foods, Tight junction proteins, Gut microbiota
The intestinal epithelial barrier is one of the most important factors in protecting gut homeostasis from continuous exposure to microbial pathogens and antigens, and is simultaneously responsible for nutrient and water uptake.1 Many previous studies have demonstrated that patients with irritable bowel syndrome (IBS) show dysfunction of the intestinal epithelial barrier and gut microbiota, which have been linked with visceral hypersensitivity and pain.2-6 Several studies have suggested mast cells as crucial effector cells of stress-induced stimulation in the intestine, which release multifunctional mediators such as proteases and histamine, leading to increase visceral hyper sensitivity.7 A recent study has shown that increases in epithelial permeability and mast cell activation by psychological stress were stronger in the small intestine than in the colon in the rats, suggesting importance of small intestinal injury in the stress-induced visceral hypersensitivity.8 Tight junctions (TJs) are essential for intestinal barrier function and regulate the paracellular permeability of materials.9 TJs are composed of more than 50 proteins including occludin family members which are transmembrane proteins.10
Recently, probiotics have been attracting increasing attention as a treatment for IBS, as many previous studies have shown that probiotics influence intestinal homeostasis, such as intestinal barrier functions, through TJ complex regulation.11-14 Traditional Japanese fermented foods contain not only eubacteria but also yeasts classified as fungi. In addition to probiotic strains belonging to eubacteria, yeasts have also been used as probiotics for treating IBS.12 However, few studies have examined the effects of yeasts from traditional Japanese fermented foods on IBS.
Miso, a fermented soybean product made from rice or barley malt and salt, is one of the most popular traditional Japanese fermented foods and seasonings. The fermentation process of miso is known to include many species of yeasts and other microorganisms.15 Miso has been reported to have positive effects in several human health conditions.16 We previously isolated a probiotic yeast strain,
In this study, we examined the effects of strain I-6 and its β-glucan on intestinal barrier dysfunction, visceral hypersensitivity in response to colorectal distension, and gut microbiota modulation in a rat model of IBS induced by water avoidance stress (WAS). To investigate the effect of strain I-6 on modulating the barrier functions of intestinal epithelial cells
Four-week-old male Wistar rats were purchased from Japan SLC Inc. (Shizuoka, Japan). Rats were housed in plastic cages with normal 12-hour light-dark cycles at a temperature of 23℃ to 24℃ with 55% humidity. The rats were fed a standard laboratory diet (CLEA Japan, Tokyo, Japan) and had free access to food and water. Laboratory animals were used in accordance with the guidelines of the “Methods and Welfare Considerations in Behavioral Research with Animals: report of a National Institutes of Health Workshop” published by the US National Institutes of Health (Bethesda, MD, USA) along the guidelines of the animal facility at the National Defense Medical College in Japan. All experimental protocols were approved by the Animal Research Committee of the National Defense Medical College (No. 18002).
Strain I-6 was obtained from our laboratory collection.17 Living strain I-6 cells were fed to the rats
Rats were divided into three groups: sham WAS+vehicle group, WAS+vehicle group, and WAS+I-6 or β-glucan group. The animals were given water with or without strain I-6 or β-glucan for 6 weeks as a pre-intervention and allowed to drink throughout the experiment. After pre-intervention, chronic WAS in rats was used as a model of IBS (Fig. 1).20,21 The WAS protocol has been described in previous reports.22 Briefly, WAS rats were placed on a glass platform (10×10 cm) in the middle of a box (46.5×37×24 cm) filled with water (23℃) to 1 cm below the height of the platform for 60 minutes per day. The rats were placed on the platform, sham WAS rats were placed in a box without water. We counted the number of stool pellets while rats were receiving WAS for 60 minutes.
Visceral hypersensitivity was evaluated using colorectal distension, as previously described with a barostatometer (Distender Series IIR; G&J Electronics Inc., Toronto, ON, Canada).23 Rats were placed in an acrylic case, and a collapsible balloon was inserted 4 cm beyond the anus of each rat under anesthesia. Balloon pressure was increased at a constant rate of 1 mm Hg/s, and the threshold of the abdominal withdrawal reflex (AWR) was measured three times; the mean value was taken as the threshold AWR value. We performed colorectal distension on the day before the start of WAS (day 0) and on the day after the end of the WAS (day 11). the changes in AWR on day 11 from day 0 (baseline) were calculated and compared among groups.
Four-week-old male Wistar rats were purchased and bred as previously described. Rats were given water with strain I-6 at a concentration of 5×106 colony-forming units per milliliter for 6 weeks, followed by collection of fresh stools. For the control groups, water was given (n=2) for free drinking. The stool samples were diluted 10-fold with phosphate-buffered saline.
Seven-week-old male Wistar rats were purchased and divided into the control group (WAS+control stool) and the I-6 group (WAS+I-6 stool) (n=6). Rats were anesthetized using isoflurane and 1 mL of stool was transgastrically administered twice daily during the WAS treatment. Visceral hypersensitivity was compared between the two groups.
Caco-2 was obtained from Riken BRC (Tsukuba, Japan) and maintained in Dulbecco’s modified Eagle’s medium containing 15% fetal bovine serum, 1% nonessential amino acids, and 1% penicillin-streptomycin solution at 37℃ and 5% CO2. The number of passages was approximately 20–40 and 1×106 cells were seeded in 6-well plates and used after 21 days with medium changes every 2 days. Cells were stimulated with recombinant interleukin-1β (IL-1β; 10 ng/mL) (Proteintech Group, Inc., Rosemont, IL, USA) at 6 hours before cell harvest. In some experiments, cells were pretreated with strain I-6 (80 µg/mL) at 48 hours before cell harvest. In some experiments, anti-Dectin-1 antibody (0.2 ng/mL) (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-TLR2 antibody (0.2 ng/mL) (Abcam, Cambridge, UK) were added 30 minutes before treatment with strain I-6.
Ileal end tissues and Caco-2 cells were homogenized in 0.5% sarcosylic acid-containing protease inhibitor (Roche Diagnostics K.K., Tokyo, Japan) and phosphatase inhibitor (Roche Diagnostics K.K.). The samples were shaken every 5 minutes for 30 minutes and then centrifuged for 5 minutes at 14,000 rpm at 4℃. The protein concentration was assessed using a DC protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). A total of 25 µg of proteins were separated in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 45 minutes at 200 V using Electrophoresis Power Supply EPS 1001 (Amersham Pharmacia Biotech, GE Healthcare, Brooklyn, NY, USA). Then it was transferred onto polyvinylidene difluoride membranes for 30 minutes at 12 V using BP-312 (BIO CRAFT, Tokyo, Japan). Membranes were blocked with 5% skim milk or 3% bovine serum albumin dissolved in phosphate buffered saline with tween 20 and incubated with the primary antibodies to occludin (Abcam) (1:1,000) and β-actin (Abcam) (1:4,000) at 4℃ overnight. After washing, the blots were incubated with anti-rabbit IgG HRP-linked antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) (1:4,000) for 1 hour at room temperature. Protein bands were detected using Clarity Western ECL Substrate (Bio-Rad Laboratories Inc.). Blot images were electronically scanned using ChemiDoc Touch (Bio-Rad Laboratories Inc.).
Stool samples were collected from sham WAS+vehicle group, sham WAS+I-6 group, WAS+vehicle group and WAS+I-6 group after completion of WAS protocol and stored at –80℃. Bacterial DNA was extracted from stool samples using the QIAamp Fast DNA stool mini kit (Qiagen, Valencia, CA, USA). The variable region V3-4 of the 16S rRNA was amplified twice by PCR using specified primers and Nextera XT Index Kit (Illumina, San Diego, CA, USA). The PCR products were purified by AMPure XP beads (Beckman Coulter Genomics, Brea, CA, USA). Library quantification, normalization, and pooling were performed according to the 16S Metagenomic Sequencing Library Preparation (Illumina). The size and quality of the pooled libraries were ascertained using MultiNA (Shimadzu Corp., Kyoto, Japan). Following NaOH denaturation, the libraries were loaded into the MiSeq reagent kit V3 and sequenced on a MiSeq instrument (Illumina). The sequence data were analyzed using the Quantitative Insights Into Microbial Ecology 2 tool.24
Comparisons among groups were undertaken using one-way analysis of variance followed by the Tukey-Kramer
WAS treatment significantly increased the number of stool pellet output per hour compared to sham WAS treatment. The WAS with strain I-6 group significantly suppressed increase in the number of stool pellets output compared to the WAS with vehicle group (Fig. 2A). In addition, WAS treatment significantly decreased the AWR threshold compared to sham WAS treatment. The WAS with I-6 group significantly suppressed the decrease in the AWR threshold compared to the WAS with vehicle group (Fig. 2B).
Increased intestinal permeability through a decrease in the TJ protein occludin results in altered intestinal permeability in IBS.25-27 The Western blotting analysis showed that the expression of occludin was decreased in the WAS with vehicle group compared to the sham WAS with vehicle group (Fig. 2C and D). This reduction was significantly inhibited by the addition of I-6 to the WAS treatment (Fig. 2C).
Furthermore, we investigated whether β-glucan extracted from the cell bodies of I-6 altered stress-induced visceral hypersensitivity, as many previous studies have shown that β-glucan is a major structural component of various yeast cells and is a potent biological agent for human and rodent experimental models.25-28
There was a significant increase in the number of stool pellets in the WAS with vehicle group compared to the sham WAS with vehicle group (Fig. 3A), but this was significantly lower in the WAS with β-glucan group compared to the WAS with vehicle group (Fig. 3A). Further, a decrease in the AWR threshold value was observed in the WAS with vehicle group compared to the sham WAS with vehicle group; these reductions were alleviated in the WAS with β-glucan group (Fig. 3B).
Analysis of the collected stool pellets showed no difference in α-diversity (Fig. 4A). In contrast, principal coordinate analysis for β-diversity indicated that the sham WAS+I-6 group had a distinctly different distribution (Fig. 4B and D) and showed significant difference by permutational multivariate analysis of variance analysis (Fig. 4C and E). The mean UniFrac distance analysis (unweighted) showed that the mean UniFrac distance between the sham WAS+vehicle group and the sham WAS+I-6 group was significantly higher than that within the sham WAS+vehicle group and within the sham WAS+I-6 group (Fig. 4B and C). Further analysis (weighted) showed that the mean UniFrac distance between the sham WAS+vehicle group and the sham WAS+I-6 group was significantly higher than that within the sham WAS+vehicle group and the sham WAS+I-6 group (Fig. 4D and E).
The composition of the gut microbiota was also analyzed. At the phylum level, there was no significant difference between the two groups in the five phyla with more than 1% abundance (Fig. 4F). At the genus level, in 29 genera with more than 1% abundance, the sham WAS+vehicle group showed significant changes in the abundance of 13 species (Fig. 4G). We applied LEfSe analysis to explore the taxa that best discriminated bacterial populations between the two groups. In the sham WAS+I-6 group, we found a pronounced deposition of the
The composition of the gut microbiota was also analyzed in stress-received animals. At the phylum level, there was no significant difference between the two groups in the five phyla with more than 1% abundance (Fig. 5A). At the genus level, in 37 genera with more than 1% abundance, the WAS+I-6 group showed significant changes in the abundance of 14 species (Fig. 5B).
To investigate whether changes in the gut microbiota are involved in the pathophysiology of the ameliorating effect of strain I-6 on stress-induced visceral hypersensitivity, we investigated whether amelioration of stress-induced visceral hypersensitivity in WAS-treated rats was transferrable by FMT from I-6 treated animals. We then compared the number of stool pellets and AWR of the control group with that of the I-6 group (Fig. 6A). There was no significant difference in the number of stool pellets (Fig. 6B). The AWR threshold value of the I-6 group was significantly higher than that of the control group (Fig. 6C).
Finally, we investigated the mechanism of I-6-induced modification of occludin expression
Here, we showed that oral administration of I-6 and β-glucan of strain I-6 ameliorated the symptoms in a rat model of IBS. The magnitude of visceral hypersensitivity and number of stool pellets were significantly smaller in the WAS with I-6 group compared with those in the WAS group. Additionally, stress-induced reduction of occludin expression in the WAS group was significantly ameliorated by I-6 treatment (Fig. 2). A previous study has reported that IBS symptoms are accompanied with an increase in intestinal permeability in a rat model of IBS, and that occludin is decreased during this process.5 Furthermore, increased intestinal permeability through a decrease in TJ proteins such as occludin is one of the main pathogenic features of human IBS, and its improvement is an important target of IBS treatment.2,4,13 These findings suggest that I-6 ameliorated the symptoms in a rat model of IBS by recovering intestinal permeability through increased occludin expression.
We then investigated whether strain I-6 directly increased the expression of occludin in intestinal epithelial cells
Although the effect of I-6 on the rat IBS model has been explained by increasing intestinal permeability, we also investigated the effects of oral administration of strain I-6 on gut microbiota, because dysbiosis is involved in the pathogenesis of IBS, and a systematic review or meta-analysis showed the usefulness of probiotic therapy in the treatment of IBS.36,37 Surprisingly, high-throughput sequencing of the gut microbiota showed significant changes in β-diversity after oral administration of strain I-6 (Fig. 4B-E). In the genus-level composition of the gut microbiota,
In conclusion,
This research was supported by grants from the National Defense Medical College.
No potential conflict of interest relevant to this article was reported.
Study concept and design: N.S., Y.O., R.H. Data acquisition: N.S., Y.O., A.T., S.I., R.T., S.N., A.M., K.I., Y.H., K.H., A.W., Y.A., M.H., C.K., S.K., K.T., R.H. Data analysis and interpretation: N.S., Y.O., R.H. Drafting of the manuscript: N.S. Critical revision of the manuscript for important intellectual content: N.S., Y.O., R.H. Statistical analysis: N.S., Y.O., R.H. Administrative, technical, or material support; study supervision: Y.O., R.H. Approval of final manuscript: all authors.